| Medical and Health Sciences | Lifetime | 793 | IT 22 | 99.96 |
| Medical and Health Sciences | 2021-2025 | 136 | IT 10 | 99.97 |
| Surgery | Lifetime | 50 | IT 3 | 99.96 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 277 | IT 18 | 99.15 |
| Cardiology and Cardiovascular Medicine | Lifetime | 805 | IT 36 | 98.29 |
| Cancer Research | Lifetime | 417 | IT 11 | 97.45 |
| Immunology | Lifetime | 871 | IT 28 | 97.11 |
| Medical Biochemistry | Lifetime | 477 | IT 21 | 85.76 |
| Surgery | 2021-2025 | 7 | IT 2 | 99.97 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 119 | IT 8 | 98.26 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 248 | IT 16 | 98.05 |
| Econometrics and Quantitative Economics | 2021-2025 | 634 | IT 23 | 96.22 |
| Cancer Research | 2021-2025 | 220 | IT 5 | 87.89 |
| Immunology | 2021-2025 | 728 | IT 25 | 76.37 |
| Lipoproteins and Cardiovascular Health | Lifetime | 18 | IT 1 | 99.86 |
| Cancer, Lipids, and Metabolism | Lifetime | 28 | IT 2 | 99.81 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 31 | IT 1 | 99.83 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 72 | IT 3 | 99.69 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 31 | IT 1 | 99.66 |
| Pharmaceutical Economics and Policy | Lifetime | 40 | IT 1 | 98.99 |
| Biomarkers in Disease Mechanisms | Lifetime | 19 | IT 4 | 98.53 |
| Cholesterol and Lipid Metabolism | Lifetime | 54 | IT 1 | 99.14 |
| Lipid metabolism and disorders | Lifetime | 47 | IT 1 | 99.15 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 310 | IT 9 | 98.55 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 311 | IT 28 | 98.48 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 534 | IT 9 | 96.60 |
| Antioxidant Activity and Oxidative Stress | Lifetime | 598 | IT 31 | 96.58 |
| Medication Adherence and Compliance | Lifetime | 325 | IT 6 | 95.52 |
| Fatty Acid Research and Health | Lifetime | 853 | IT 24 | 95.08 |
| Microbial Metabolism and Applications | Lifetime | 610 | IT 24 | 92.17 |
| Cardiovascular Health and Risk Factors | Lifetime | 832 | IT 13 | 90.77 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 958 | IT 11 | 85.00 |
| Aortic Thrombus and Embolism | Lifetime | 692 | IT 22 | 67.45 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 7 | IT 1 | 99.75 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 5 | IT 1 | 99.83 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 6 | IT 1 | 99.89 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 10 | IT 1 | 99.69 |
| Lipid metabolism and disorders | 2021-2025 | 7 | IT 1 | 98.94 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 78 | IT 13 | 97.62 |
| Pharmaceutical Economics and Policy | 2021-2025 | 38 | IT 3 | 96.60 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 180 | IT 7 | 91.64 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 397 | IT 11 | 85.58 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 559 | IT 46 | 61.38 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 915 | IT 35 | 54.45 |
